KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) Capital Expenditures (2016 - 2022)

Palvella Therapeutics (PVLA) has disclosed Capital Expenditures for 10 consecutive years, with -$184000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Capital Expenditures fell 1572.73% to -$184000.0 in Q4 2023 year-over-year; TTM through Sep 2024 was -$184000.0, a 206.36% decrease, with the full-year FY2022 number at $1.0 million, up 339.24% from a year prior.
  • Capital Expenditures was -$184000.0 for Q4 2023 at Palvella Therapeutics, down from $110000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.9 million in Q1 2020 to a low of -$840000.0 in Q3 2020.
  • A 5-year average of $323300.0 and a median of $175000.0 in 2019 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: skyrocketed 1492.56% in 2020, then plummeted 1572.73% in 2023.
  • Palvella Therapeutics' Capital Expenditures stood at $1.2 million in 2019, then plummeted by 50.85% to $578000.0 in 2020, then crashed by 164.01% to -$370000.0 in 2021, then skyrocketed by 97.03% to -$11000.0 in 2022, then tumbled by 1572.73% to -$184000.0 in 2023.
  • Per Business Quant, the three most recent readings for PVLA's Capital Expenditures are -$184000.0 (Q4 2023), $110000.0 (Q3 2023), and $26000.0 (Q2 2023).